{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:56Z","timestamp":1747181156327,"version":"3.40.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,24]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>B-cell acute lymphoblastic leukemia (B-ALL) is a neoplasm of immature B-cells that is more prevalent in children. Despite successful remission rates in patients with B-ALL on chemotherapy, the risk of relapse is high. This has paved way for highly active immune and cell therapies to be intensively explored. However, the efficacy and immune-related adverse events (AE) associated with the use of immunotherapies remain elusive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This protocol has been prepared in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 guidelines. Cochrane Central Register of Controlled Trials, MEDLINE, and Embase electronic databases will be searched to retrieve relevant interventional studies. Two reviewers (BKK and EH) will autonomously search and identify relevant studies using a preset inclusion and exclusion criteria. A predefined data extraction sheet will be used to extract relevant data items. The risk of bias will be assessed by 2 reviewers (BKK and BBN) using the Cochrane risk-of-bias tool for randomized controlled trials and the Downs and Black Checklist for nonrandomized controlled trials. A third reviewer (TMN) will be consulted for any discrepancies. The Grading of Recommendations Assessment Development and Evaluation will be used to assess the strengths of evidence by 2 reviewers (BBK and TMN). The <jats:italic toggle=\"yes\">I<\/jats:italic>\u00b2 and Chi-squared statistical tests will be used to investigate statistical heterogeneity across studies. An <jats:italic toggle=\"yes\">I<\/jats:italic>\u00b2 value of\u2005&gt;\u200550% will be considered substantial heterogeneity and a random-effects model will be used. Data analysis will be performed using Review Manager (RevMan V.5.3) statistical software.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032987","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T13:08:23Z","timestamp":1679663303000},"page":"e32987","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immune-related adverse events associated with the use of immunotherapy in patients with B-cell lymphoblastic leukemia: A protocol for a systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Bianca K.","family":"Kanovengi","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bongani B.","family":"Nkambule","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwig","family":"Hauwanga","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-9524","authenticated-orcid":false,"given":"Tawanda M.","family":"Nyambuya","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Windhoek, Namibia"},{"name":"School of Pathology, Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"22869","article-title":"Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017.","volume":"12","author":"Ming","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017.","volume":"9","author":"Dong","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3892\/ol.2020.11583","article-title":"Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: molecular pathways and disease treatments (Review).","volume":"20","author":"Huang","year":"2020","journal-title":"Oncol Lett"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update.","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children.","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia.","volume":"105","author":"Mullighan","year":"2020","journal-title":"Haematologica"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia.","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia.","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JOP.18.00271","article-title":"Acute lymphoblastic leukemia in the older adult.","volume":"15","author":"Aldoss","year":"2022","journal-title":"J Oncol Pract"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard care for acute lymphoblastic leukemia.","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/cas.14322","article-title":"Phase 1b\/2 study of blinatumomab in Japanese adults with relapsed\/refractory acute lymphoblastic leukemia.","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-Cell ALL patients achieving MRD-negative CR after CD19 CAR T-Cell therapy.","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/ajco.13609","article-title":"Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia.","volume":"18","author":"Kobayashi","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/apjon.apjon_6_19","article-title":"Adverse events of oncologic immunotherapy and their management.","volume":"6","author":"Barber","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.01594","article-title":"Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: state of the art and future directions.","volume":"10","author":"Greenbaum","year":"2020","journal-title":"Front Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells BiTEs and beyond.","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:36:28Z","timestamp":1746326188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032987","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}